Stay updated on SY-1425 Biomarker-Directed Trial in AML/MDS Clinical Trial
Sign up to get notified when there's something new on the SY-1425 Biomarker-Directed Trial in AML/MDS Clinical Trial page.

Latest updates to the SY-1425 Biomarker-Directed Trial in AML/MDS Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedRevision: v3.4.2 is now displayed, replacing Revision: v3.4.1. No core study details or results appear to be altered.SummaryDifference0.0%

- Check19 days agoChange DetectedA new Revision: v3.4.1 entry was added and the previous Revision: v3.4.0 entry was removed.SummaryDifference0.0%

- Check41 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4 on the site, with no evident changes to the study details, eligibility criteria, locations, or outcomes. This appears to be a non-substantive update focused on the site's versioning. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check62 days agoChange DetectedLocations section now lists participating states (Connecticut, Florida, Iowa, Massachusetts, Michigan, New York, North Carolina, Ohio, Oregon, Pennsylvania, Tennessee, Texas). The HHS Vulnerability Disclosure link was removed.SummaryDifference1%

- Check91 days agoChange DetectedAdded a PubMed auto-fill note stating that publications may not be about the study and included a page revision tag (v3.3.2). Removed the prior PubMed-source note and the older revision tag (v3.2.0).SummaryDifference0.1%

- Check99 days agoChange DetectedThe funding lapse notice was removed from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

Stay in the know with updates to SY-1425 Biomarker-Directed Trial in AML/MDS Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SY-1425 Biomarker-Directed Trial in AML/MDS Clinical Trial page.